Massachusetts General Hospital has received a $750,000 human clinical trial grant to explore the use of positron emission tomography imaging of inflammation to serve as a biomarker for amyotrophic lateral sclerosis diagnosis and clinical trials.
The Muscular Dystrophy Association (MDA) has awarded Massachusetts General Hospital (MGH) a $750,000 human clinical trial grant for the development of treatments for amyotrophic lateral sclerosis (ALS), known as Lou Gehrig's disease, according to a press release.
ALS ONE, a partnership among leaders in ALS treatment—MGH, ALS Therapy Development Institute, the University of Massachusetts Medical School, and Compassionate Care ALS—developed the grant. This partnership was created in January 2016 to expedite ALS treatments and to develop new approaches to improve ALS care.
The MDA grant intends to specifically fund research that explores the use of positron emission tomography (PET) imaging of inflammation to serve as a biomarker for ALS diagnosis and clinical trials, according to the press release.
“This project is poised to change the paradigm of ALS drug development and have a direct impact on the design of future treatment trials for both familial and sporadic ALS,” said Nazem Atassi, MD, MMSc, member of the ALS ONE Science Team, Associate Director for the Neurological Clinical Research Institute at Massachusetts General Hospital, and Associate Professor of Neurology at Harvard Medical School.
Patients with ALS often lose the ability to control their muscle movements leading to total paralysis and death, typically within 5 years of diagnosis. One of the challenges with ALS drug development is the lack of existing biomarkers that demonstrate the efficacy of the drugs in patients.
MGH’s Neurological Clinical Research Institute is assessing the ability of PET imaging in order to measure the inflammation in the brain of ALS patients; previous studies have shown ALS patients with more inflammation tend to have greater disease progression. The novel PET imaging that the grant would fund could potentially decrease the duration of future trials from 12 months to just 3 months and decrease the required patient enrollment from 400 to just 30; therefore, increasing the efficiency of ALS drug development.
Atassi explained that the funding can allow researchers to better characterize the onset and progression of brain inflammation in patients with early ALS symptoms and in people who are asymptomatic but carry ALS genes.
"At MDA, we are hopeful that this project will build upon recent advances in biomarker development for ALS to not only accelerate drug development, but also provide meaningful insights into the course of inflammation in people with ALS," said MDA Scientific Program Officer Amanda Haidet-Phillips, PhD.
The development and use of biomarker tools will encourage new biotech pharma entrants to develop more safe and effective treatments for people with ALS, MDA stated.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More